Results 81 to 90 of about 83,065 (165)

Withdrawal pain following patients discontinuing Trk inhibitors. [PDF]

OBJECTIVE: This article aims to expand on the existing literature regarding the incidence of withdrawal pain following discontinuation of Trk inhibitors and to explore strategies that mitigate this withdrawal pain.
Lindsay, Sheila, Chin, Alan, Bergsland, Emily, Kang, Hyunseok   +3 more
core   +1 more source

SELEKSI JAMUR PELAPUK PUTIH HUTAN TROPIS INDONESIA SEBAGAI PENGHASIL ENZIM LAKASE (Lac) DAN MANGAN PEROKSIDASE (MnP)

Jurnal Penelitian Hasil Hutan (Journal of Forest Products Research), 2017
Jamur pelapuk putih Basidiomycetes adalah kelompok mikroba yang sangat unik. Secara alami mereka dapat mendekomposisi biomassa berlignoselulosa.
Lisna Efiyanti, Asep Hidayat
doaj   +1 more source

Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer

, 2019
Introduction: Detecting oncogenic drivers across multiple cancers has brought about a shift toward a more targeted therapeutic approach. Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are genomic rearrangements containing the kinase domain of ...
Noah Federman (799643), Ray McDermott (112352)   +1 more
core   +1 more source

Synthesis and In Silico Evaluation of the Ninhydrin Derivatives Interaction with Target Proteins Involved in Cancer Pathogenesis and Progression

Organics
Ninhydrins represent a promising chemical space for the search for new biologically active molecules with antimicrobial, antiprotease, and antitumor properties.
Anastasia R. Kovrizhina, Andrei I. Khlebnikov   +1 more
doaj   +1 more source

Abstract 4179: Potent and selective TRK inhibitor CH7057288

, 2017
TRK receptor tyrosine kinases are expressed as fusion proteins encoded by various fusion genes across a wide variety of cancer types, including lung and colorectal cancer.
Kiyoshi Hasegawa, Toshiyuki Tsukaguchi, Hiroshi Sakamoto, Hiroshi Tanaka, Yoshiyuki Ono, Hitoshi Sase, Nobuhiro Oikawa, Toshiyuki Mio, Hiromi Tanimura, Masami Hasegawa   +9 more
core   +1 more source

Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib

Acta Pharmaceutica Sinica B
Neurotrophic receptor kinase (NTRK) fusions are actionable oncogenic drivers of multiple pediatric and adult solid tumors, and tropomyosin receptor kinase (TRK) has been considered as an attractive therapeutic target for “pan-cancer” harboring these ...
Shuang Xiang, Xiaoyun Lu
doaj   +1 more source

Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammation.

PLoS ONE, 2013
Receptor tyrosine kinases (RTKs), in response to their growth factor ligands, phosphorylate and activate downstream signals important for physiological development and pathological transformation.
Ramesh Narayanan, Muralimohan Yepuru, Christopher C Coss, Zhongzhi Wu, Matthew N Bauler, Christina M Barrett, Michael L Mohler, Yun Wang, Juhyun Kim, Linda M Snyder, Yali He, Nelson Levy, Duane D Miller, James T Dalton   +13 more
doaj   +1 more source

Validation and interpretation of Pan-TRK immunohistochemistry: a practical approach and challenges with interpretation

Diagnostic Pathology
Objectives Actionable, solid tumor activating neurotrophic receptor tyrosine kinase (NTRK) fusions are best detected via nucleic acid-based assays, while Pan-TRK immunohistochemistry (IHC) serves as a reasonable screening modality.
Cansu Karakas, Ellen J. Giampoli, Tanzy Love, David G. Hicks, Moises J. Velez   +4 more
doaj   +1 more source

Identification of 4-Aminopyrazolylpyrimidines as Potent Inhibitors of Trk Kinases

, 2016
The design, synthesis and biological evaluation of a series of 4-aminopyrazolylpyrimidines as potent Trk kinase inhibitors is reported. High-throughput screening identified a promising hit in the 4-aminopyrazolylpyrimidine chemotype. Initial optimization
Michelle L. Lamb (1545151), John W. Lee (2094133), Ethan Hoffmann (1613374), Ken Thress (2425075), Dingwei Yu (2044984), Tao Wang (12008), Haiyun Wang (27725), David A. Scott (135462), Peter J. Mohr (1706467), Charles A. Omer (2044990), Hai-Jun Zhang (1529818), Haixia Wang (173360), Michael H. Block (1705567), Fei Gu (23867), Robert J. Kaus (2425081), Terry MacIntyre (1864681), John A. Josey (1833421), Paul D. Lyne (1427734), Audrey M. Davies (2160172), Bin Wang (30851), Yongxin Han (1235268), Yanyi Zhu (2425078)   +21 more
core   +1 more source

Pyrazolo[1,5-a]pyrimidine as a Prominent Framework for Tropomyosin Receptor Kinase (Trk) Inhibitors—Synthetic Strategies and SAR Insights

Molecules
Tropomyosin receptor kinases (Trks) are transmembrane receptor tyrosine kinases named TrkA, TrkB, and TrkC and encoded by the NTRK1, NTRK2, and NTRK3 genes, respectively.
Amol T. Mahajan, Shivani, Ashok Kumar Datusalia, Carmine Coluccini, Paolo Coghi, Sandeep Chaudhary   +5 more
doaj   +1 more source